Seminars in Arthritis and Rheumatism
Volume 39, Issue 4 , Pages 278-284 , February 2010

Natriuretic Peptides in Systemic Sclerosis-related Pulmonary Arterial Hypertension

  • Theodoros Dimitroulas, MD

      Affiliations

    • Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece
    • Corresponding Author InformationAddress reprint requests to: Theodoros Dimitroulas, MD, Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Stilp. Kiriakidi 1, 54636, Thessaloniki, Greece
    • ,
  • Georgios Giannakoulas, MD, PhD

      Affiliations

    • Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK
    • Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece
    • ,
  • Haralambos Karvounis, MD, PhD

      Affiliations

    • Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece
    • ,
  • Michael A. Gatzoulis, MD, PhD

      Affiliations

    • Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK
    • ,
  • Loucas Settas, MD, PhD

      Affiliations

    • Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece

References 

  1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940–944
  2. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792–3800
  3. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088–1093
  4. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123:344–350
  5. Lindqvist P, Caidahl K, Neuman-Andersen G, Ozolins C, Rantapää-Dahlqvist S, Waldenström A, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest. 2005;128:755–763
  6. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marineli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48:2546–2552
  7. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest. 2004;126:1330–1336
  8. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78–81
  9. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev. 2003;24:341–356
  10. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322
  11. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J. 1998;135:914–923
  12. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility. Curr Opin Crit Care. 2004;10:336–341
  13. McCullough PA, Duc P, Omland T, McCord G, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571–579
  14. Wong F, Blendis L. Pathophysiology of sodium retention and ascites formation in cirrhosis: role of atrial natriuretic factor. Semin Liver Dis. 1994;14:59–70
  15. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med. 2003;31:2611–2618
  16. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–2368
  17. Muders F, Kromer EP, Griese DP, Pfeifer M, Hense HW, Riegger GA, et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J. 1997;134:442–449
  18. Masson S, Vago T, Baldi G, Salio M, De Angelis N, Nikolis E, et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med. 2002;40:761–763
  19. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens. 1999;12:921–924
  20. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction (Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide). Circulation. 1996;93:1963–1969
  21. Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, et al. Natriuretic peptides in unstable coronary artery disease. Eur Heart J. 2004;25:1486–1493
  22. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjørnerheim R, Endresen K, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J. 2001;142:725–732
  23. Efthimiadis GK, Hitoglou-Makedou A, Giannakoulas G, Mitakidou A, Karamitsos T, Karvounis H, et al. Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy. Heart Vessels. 2007;22:322–327
  24. Hasegawa K, Fujiwara H, Doyama K, Mukoyama M, Nakao K, Fujiwara T, et al. Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy (An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies). Am J Pathol. 1993;142:107–116
  25. Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke. 2002;33:1005–1010
  26. Nakanishi K, Tajima F, Itoh H, Nakata Y, Osada H, Hama N, et al. Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia-induced pulmonary hypertension in rats. Virchows Arch. 2001;439:808–817
  27. Buckley MG, Sethi D, Markandu ND, Sagnella GA, Singer DR, MacGregor GA. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci. 1992;83:437–444
  28. Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology. 2005;56:723–730
  29. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997;349:245–249
  30. Jones AE, Kline JA. Elevated brain natriuretic peptide in septic patients without heart failure. Ann Emerg Med. 2003;42:714–715
  31. Klinger JR, Arnal F, Warburton RR, Ou LC, Hill NS. Downregulation of pulmonary atrial natriuretic peptide receptors in rats exposed to chronic hypoxia. J Appl Physiol. 1994;77:1309–1316
  32. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:202–208
  33. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest. 2005;128:2368–2374
  34. Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin. 2005;21:907–911
  35. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29:737–744
  36. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865–870
  37. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129:1313–1321
  38. Mukerjee D, Yap LB, Holmes AM, Nair D, Ayrton P, Black CM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med. 2003;97:1230–1236
  39. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum. 2003;48:3503–3508
  40. Emdin M, Marini C, Passino C, Giuggioli D, Formichi B, Ferri C, et al. Right ventricular overload and cardiovascular neuroendocrine derangement in systemic sclerosis. Eur Heart J. 2004;6(Suppl F):F68–F73
  41. Dimitroulas T, Giannakoulas G, Karvounis H, Sfetsios T, Koliakos G, Parcharidis G, et al. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol. 2007;121:135–137
  42. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485–1494
  43. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002;106:92–99
  44. Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Gierhl W, Vogeser M, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2004;170:360–365
  45. Reesink HJ, Tulevski II, Marcus J, Boomsma F, Kloek JJ, Vonk Noordegraaf A, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2007;84:537–543
  46. Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E, et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptideconcentrations. Haematologica. 2007;92:738–743
  47. Krüger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J. 2004;147:60–65
  48. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol. 2004;43:416–422
  49. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics. 2004;114:1297–1304
  50. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol. 1997;47:287–296
  51. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta. 2004;341:41–48
  52. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58:284–291
  53. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Ohlin AK, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology. 2005;44:366–371
  54. Ciurzyński M, Bienias P, Lichodziejewska B, Kurnicka K, Szewczyk A, Glińska-Wielochowska M, et al. Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol. 2008;27:991–997
  55. Dimitroulas T, Giannakoulas G, Karvounis H, Koliakos G, Sfetsios T, Dimitroula H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol. 2008;27:655–658
  56. Simeoni S, Lippi G, Puccetti A, Montagnana M, Tinazzi E, Prati D, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int. 2008;28:657–660
  57. Hayakawa I, Shirasaki F, Hirano T, Oishi N, Hasegawa M, Sato S, et al. Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int. 2006;26:270–273
  58. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101:113–129
  59. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction?. J Rheumatol. 1994;21:1838–1844
  60. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes (A paracrine mechanism for myocardial cell hypertrophy). J Biol Chem. 1990;265:2055–2062
  61. Han B, Lenggoro IW, Choi M, Okuyama K. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther. 2003;17:41–52
  62. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97:4239–4244
  63. Montagnana M, Lippi G, Volpe A, Salvagno GL, Biasi D, Caramaschi P, et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem. 2006;39:913–917
  64. Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998; Evian, France, September 6-10, 1998, cosponsored by the World Health Organization.
  65. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(Suppl 1):14S–34S
  66. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167:735–740
  67. Brecker SJ, Gibbs JS, Fox KM, Yacoub MH, Gibson DG. Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. Br Heart J. 1994;72:384–389
  68. Allanore Y, Wahbi K, Borderie D, Weber S, Kahan A, Meune C. N-terminal brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?. Ann Rheum Dis. 2009;(in press)
  69. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32:503–512
  70. Knudsen CW, Clopton P, Westheim A, Klemsdal TO, Wu AH, Duc P, et al. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. Ann Emerg Med. 2005;45:573–580
  71. Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007;131:402–409
  72. Dimitroulas T, Giannakoulas G, Karvounis H, Settas L. Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: comment on the article by Allanore et al. Arthritis Rheum. 2008;58:2215–2216
  73. Meune C, Allanore Y, Pascal O, Devaux JY, Dessault O, Duboc D, et al. Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr. 2005;6:351–357
  74. D'Andrea A, Stisi S, Bellisimo S, Vigorito F, Scotto di Uccio F, Tozzi N, et al. Early impairment of myocardial function in systemic sclerosis: noninvasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr. 2005;6:407–418

 The first 2 authors contributed equally to this work.

 The authors have no conflicts of interest to disclose.

 Dr Giannakoulas has received training and research grants from the Hellenic Cardiological Society, the Hellenic Heart Foundation, and the DG Education & Culture–LLP Programme–Leonardo Da Vinci Mobility. Professor Gatzoulis and the Royal Brompton Adult Congenital Heart Centre and Centre for Pulmonary Hypertension have received support from the British Heart Foundation.

PII: S0049-0172(09)00038-9

doi: 10.1016/j.semarthrit.2009.03.005

Seminars in Arthritis and Rheumatism
Volume 39, Issue 4 , Pages 278-284 , February 2010

Article Tools

* Image Usage & Resolution